脱氢表雄酮硫酸酯治疗男性骨质疏松症的临床观察

目的　观察脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效、安全性。方法　随机单盲对照观察脱氢表雄酮硫酸酯 (DHEAS)服用六个月前后骨密度 (BMD)、血生化指标、骨吸收指标和骨形成指标 ,副作用等方面的变化。结果　治疗后治疗组脱氢表雄酮硫酸酯 (DHEAS)、类胰岛素生长因子 Ⅰ (IGF Ⅰ )较治疗前分别提高 (93 75±16 1) %、(17 71± 4 2 ) % ,较对照组明显提高 (P <0 0 1)。腰 2、腰 3、腰 4的骨密度 (BMD)较治疗前分别提高(2 6 5± 0 6 2 ) %、(2 70± 0 4 8) %、(3 10± 0 4 1) % ,腰 2 - 4较治疗前提高 (2 82± 0 37) % ,股骨颈的BND较治疗前提高 (2 32± 0 32 ) %。腰 2、腰 3、腰 4、腰 2 4、股骨颈的BMD上升幅度较大与对照组差别有显著性 (P <0 0 5 ,0 0 1)。游离睾丸酮 (FT)、雌二醇 (E2 )、前列特异抗原 (PSA)则无明显影响。结论　脱氢表雄酮硫酸酯治疗男性骨质疏松症的疗效安全可靠 ,无不良反应。

Treatment of osteoporosis in men using dehydroepiandrosterone sulfate

Objective To study the effect of dehydroepiandrosterone sulfate (DHEAS) treatment of osteoporosis in men with TBMD≥2.5SD. Methods Eighty-six patients were randomly divided into two groups: treatment group (n=44) and control group (n=42). DHEAS (100?mg q.d.) was given to the treatment group for 6 months. Bone mineral density, (BMD), biochemical markers of bone absorption and formation and other serum biochemical markers were measured before and after DHEAS treatment. Drug side effects were also evaluated. Results After oral administration of DHEAS (100?mg q.d.) for 6 months, the serum concentrations of DHEAS and IGF-Ⅰ in the treatment group were 93.75%±16.1% and 17.71%±4.2% higher respectively than those in the control group (P<0.01). The BMD of L2, L3, L4, L2-4 and Neck sections increased in the treatment group by 2.65%±0.65%, 2.70%±0.48%, 3.10%±0.41%, 2.82%±0.37% and 2.32%±0.31%, respectively, as compared with that the control group (P<0.05 or 0.01). No significant changes were observed in serum FT, E2 and PSA concentrations in the treatment group as compared with the control group. Conclusion The treatment of osteoporosis in men with DHEAS is safe and effective.